Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV

These initial clinical data support the further development of MV-012-968 for RSV and the application of Meissas technology to a COVID-19 vaccine candidate.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, June 30, 2020
Information
Tags: 
FDA, Health, Infectious diseases, Other Health, Pharmaceutical, Biotechnology, Vaccination, Virology, Severe acute respiratory syndrome-related coronavirus, Attenuated vaccine, Vaccine, Branches of biology, Biology, Organisms
Geotags: 
United States, California
⚠ generated by AI ↴
Organisation: 
MEISSA VACCINES
Summary
Key Points: 
  • These initial clinical data support the further development of MV-012-968 for RSV and the application of Meissas technology to a COVID-19 vaccine candidate.
  • Meissas COVID-19 vaccine candidate, MV-014-210, was developed on the companys codon deoptimized RSV vaccine platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines.
  • Meissas COVID-19 vaccine candidate, MV-014-210, was derived by modifying the companys RSV LAV candidate, MV-012-968, replacing the RSV glycoproteins with a functioning SARS-CoV-2 Spike protein.
  • Furthermore, building our COVID-19 vaccine candidate on our RSV vaccine platform provides safety advantages compared to a live attenuated coronavirus approach.


Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the company has initiated preclinical studies and manufacturing and completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for the development of MV-014-210, a live attenuated vaccine (LAV) candidate to induce immunity and protect against SARS-CoV-2, the novel coronavirus that causes COVID-19. Meissa also announced today interim results from the first-in-human study of MV-012-968, the company’s LAV candidate for respiratory syncytial virus (RSV), showing MV-012-968 generates an immune response in healthy adults. These initial clinical data support the further development of MV-012-968 for RSV and the application of Meissa’s technology to a COVID-19 vaccine candidate.

Meissa’s COVID-19 vaccine candidate, MV-014-210, was developed on the company’s codon deoptimized RSV vaccine platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines. The company’s platform technology can potentially solve challenging obstacles in modern vaccinology such as suboptimal immune responses, vaccine stability, and manufacturing.

Meissa’s COVID-19 vaccine candidate, MV-014-210, was derived by modifying the company’s RSV LAV candidate, MV-012-968, replacing the RSV glycoproteins with a functioning SARS-CoV-2 Spike protein. Meissa’s COVID-19 vaccine candidate offers significant potential advantages for global deployment, including needle-free intranasal administration, a single adjuvant-free dose to induce systemic and mucosal immunity, and a straightforward, economical, and scalable manufacturing process capable of supplying global demands. Clinical trials are expected to begin in early 2021.

“The COVID-19 vaccine pipeline is dominated by non-replicating vaccines, while live attenuated vaccines are known to induce long-lasting immunity after a single adjuvant-free dose, presenting an economical and effective solution to this global pandemic,” said Martin Moore, Ph.D., cofounder and CEO of Meissa. “A single dose of MV-014-210 may be sufficient to generate immunity against SARS-CoV-2. Furthermore, building our COVID-19 vaccine candidate on our RSV vaccine platform provides safety advantages compared to a live attenuated coronavirus approach.”

In animal models evaluated previously, Meissa’s RSV LAV candidate MV-012-968 induced a strong mucosal IgA response and a serum-neutralizing antibody response against RSV. MV-012-968 has been safe and well-tolerated among healthy RSV sero-low adults assessed through day 56 in an ongoing randomized, open-label, dose-ranging Phase 1a trial (ClinicalTrials.gov Identifier NCT04227210). A 106 PFU dose of MV-012-968 resulted in no detectable shed vaccine virus nasally, indicating heavy attenuation, and yet induced RSV-specific mucosal IgA in the majority of vaccine recipients, despite pre-existing immunity to RSV.

Dr. Moore concluded, “The promising clinical data from our RSV vaccine candidate showing that it generated an immune response and has been safe and well-tolerated in healthy individuals further supports the application of Meissa’s technology to a COVID-19 vaccine candidate as well as continued development of MV-012-968 for RSV.”

About Meissa Vaccines

Meissa is a private biotechnology company focused on the advancement of vaccines for respiratory viruses. Meissa was founded on proprietary technologies employing reverse genetics for rational design of more effective live attenuated vaccines. The technology is exclusively licensed from Emory University and Children’s Healthcare of Atlanta. Dr. Moore, together with Dr. Roderick Tang, a vaccine biotech expert, cofounded Meissa. They are supported by a team with extensive experience in all aspects of vaccine development. Meissa is currently a resident company at Johnson & Johnson Innovation – JLABS in South San Francisco. For more information, please visit www.meissavaccines.com.

Copyright: 
Copyright Business Wire 2020